{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:01:02Z","timestamp":1775570462677,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.7759\/cureus.103224","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:56:52Z","timestamp":1770598612000},"source":"Crossref","is-referenced-by-count":1,"title":["Reversible Thrombocytopenia Associated With Rosuvastatin Use: A Case Report"],"prefix":"10.7759","author":[{"given":"Rida","family":"Mobeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amen","family":"Mobeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101342","article-title":"Lipid lowering therapy: an era beyond statins","volume":"47","author":"Abdul-Rahman T","year":"2022","unstructured":"Abdul-Rahman T, Bukhari SMA, Herrera EC, et al.. Lipid lowering therapy: an era beyond statins. Curr Probl Cardiol. 2022, 47:101342-10. 10.1016\/j.cpcardiol.2022.101342","journal-title":"Curr Probl Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242424","article-title":"Statin adherence is lower in primary than secondary prevention: a national follow-up study of new users","volume":"19","author":"Sigglekow F","year":"2020","unstructured":"Sigglekow F, Horsburgh S, Parkin L. Statin adherence is lower in primary than secondary prevention: a national follow-up study of new users. PLoS One. 2020, 19:0242424. 10.1371\/journal.pone.0242424","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22147","article-title":"Landmark lipid-lowering trials in the primary prevention of cardiovascular disease","volume":"36","author":"Chrispin J","year":"2013","unstructured":"Chrispin J, Martin SS, Hasan RK, et al.. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease. Clin Cardiol. 2013, 36:516-23. 10.1002\/clc.22147","journal-title":"Clin Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12502","article-title":"Atorvastatin-induced refractory thrombocytopenia","volume":"5","author":"Ghuman J","year":"2021","unstructured":"Ghuman J, Manasewitsch NT, Ghuman J, Antwi-Amoabeng D, Chahal G. Atorvastatin-induced refractory thrombocytopenia. Cureus. 2021, 5:12502. 10.7759\/cureus.12502","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6515\/acs20160611a","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"Ramkumar S","year":"2016","unstructured":"Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016, 32:631-9. 10.6515\/acs20160611a","journal-title":"Acta Cardiol Sin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181e170f5","article-title":"Rosuvastatin-induced thrombocytopenia","volume":"103","author":"Vrettos I","year":"2010","unstructured":"Vrettos I, Papageorgiou S, Economopoulou C, et al.. Rosuvastatin-induced thrombocytopenia. South Med J. 2010, 103:676-8. 10.1097\/SMJ.0b013e3181e170f5","journal-title":"South Med J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121536","article-title":"Post-marketing surveillance of statins: a descriptive analysis of psychiatric adverse reactions in EudraVigilance","volume":"10","author":"Pop G","year":"2022","unstructured":"Pop G, Farca\u0219 A, Butuc\u0103 A, et al.. Post-marketing surveillance of statins: a descriptive analysis of psychiatric adverse reactions in EudraVigilance. Pharmaceuticals (Basel). 2022, 10:1536. 10.3390\/ph15121536","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0975-2870.167984","article-title":"Atorvastatin-induced thrombocytopenia: a case report and review of literature","volume":"9","author":"Moitra S","year":"2016","unstructured":"Moitra S, Sen S, Das P, Banerjee I. Atorvastatin-induced thrombocytopenia: a case report and review of literature. Med J DY Patil Univ. 2016, 9:117-20. 10.4103\/0975-2870.167984","journal-title":"Med J DY Patil Univ"},{"key":"ref9","unstructured":"The use of the WHO-UMC system for standardized case causality assessment. (2025). Accessed. February 7, 2026: https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462074-reversible-thrombocytopenia-associated-with-rosuvastatin-use-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:56:53Z","timestamp":1770598613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462074-reversible-thrombocytopenia-associated-with-rosuvastatin-use-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.103224","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,8]]}}}